menu
    • menu
    [{"orgOrder":0,"company":"DiscGenics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"","productType":"Cell and Gene therapy","year":"2021","type":"Not Applicable","leadProduct":"Rebonuputemcel","moa":"","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase I\/ Phase II","graph3":"DiscGenics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Intradiscal injection","sponsorNew":"DiscGenics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"DiscGenics \/ Not Applicable"},{"orgOrder":0,"company":"DiscGenics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"","productType":"Cell and Gene therapy","year":"2022","type":"Not Applicable","leadProduct":"Allogeneic Discogenic Progenitor Cell Therapy","moa":"","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase I\/ Phase II","graph3":"DiscGenics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"DiscGenics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"DiscGenics \/ Not Applicable"},{"orgOrder":0,"company":"DiscGenics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"","productType":"Cell and Gene therapy","year":"2024","type":"Not Applicable","leadProduct":"Rebonuputemcel","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"DiscGenics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"DiscGenics \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"DiscGenics \/ Not Applicable"}]

    Find Clinical Drug Pipeline Developments & Deals by DiscGenics

    Menu

    DiscGenics

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            DiscGenics

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            DiscGenics

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Rebonuputemcel

                            Therapeutic Area : Orthopedics/Orthopedic Surgery

                            Study Phase : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            DiscGenics Gets FDA Nod for Phase III Trial of Injectable Disc Progenitor Cells

                            Details : Rebonuputemcel is an allogeneic, injectable disc progenitor cell therapy, is under investgaten for painful lumbar degenerative disc disease.

                            Brand Name : IDCT

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Not Applicable

                            July 16, 2024

                            Lead Product(s) : Rebonuputemcel

                            Therapeutic Area : Orthopedics/Orthopedic Surgery

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            DiscGenics

                            U.S.A arrow
                            Fi Europe 2024
                            Not Confirmed

                            DiscGenics

                            U.S.A arrow
                            Fi Europe 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Allogeneic Discogenic Progenitor Cell Therapy

                            Therapeutic Area : Orthopedics/Orthopedic Surgery

                            Study Phase : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Two-Year Clinical Data for DiscGenics's Progenitor Cell Therapy for Lumbar Disc Degeneration to Be Presented a...

                            Details : High dose IDCT (Allogeneic Discogenic Progenitor Cell Therapy) also produced clinically meaningful, statistically significant improvements in function and quality of life by 12 weeks following intradiscal injection with durability sustained at the one-ye...

                            Brand Name : IDCT

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Not Applicable

                            October 11, 2022

                            Lead Product(s) : Allogeneic Discogenic Progenitor Cell Therapy

                            Therapeutic Area : Orthopedics/Orthopedic Surgery

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            DiscGenics

                            U.S.A arrow
                            Fi Europe 2024
                            Not Confirmed

                            DiscGenics

                            U.S.A arrow
                            Fi Europe 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Rebonuputemcel

                            Therapeutic Area : Orthopedics/Orthopedic Surgery

                            Study Phase : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            DiscGenics Completes Patient Enrollment in Japanese Clinical Study of Cell Therapy for Disc Degeneration

                            Details : This prospective, randomized, double-blinded, sham-controlled, multicenter clinical study is designed to evaluate the safety and preliminary efficacy of IDCT in patients with symptomatic, single-level, mild to moderate lumbar disc degeneration.

                            Brand Name : IDCT

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Not Applicable

                            April 27, 2021

                            Lead Product(s) : Rebonuputemcel

                            Therapeutic Area : Orthopedics/Orthopedic Surgery

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth